CD3+CD56+NKT细胞及CD3-CD56+NK细胞在恶性肿瘤患者的临床意义研究

背景与目的细胞毒性淋巴细胞在抗肿瘤免疫效应中发挥着重要作用,CD3 CD56 NKT细胞作为一类新的具有细胞毒性的效应细胞,目前关于其抗肿瘤意义的探讨主要集中于血液系统恶性疾病,而在实体肿瘤中的应用和临床价值研究尚少。本研究旨在初步探讨抗肿瘤细胞CD3 CD56 NKT细胞及CD3-CD56 NK细胞在恶性肿瘤患者外周血的表达状态及其临床意义。方法采用流式细胞术分析118例恶性肿瘤患者(55例肺癌患者和63例乳腺癌患者)及46例健康对照组外周血中的T细胞亚群及CD3 CD56 NKT细胞、CD3-CD56 NK细胞表达。结果恶性肿瘤患者组CD3 CD8 T细胞、CD3 CD56 NKT细胞以及CD3-CD56 NK细胞表达率均明显高于健康对照组(P<0.01)。肺癌患者中以CD3 CD8 T细胞和CD3 CD56 NKT细胞明显增加为主;乳腺癌患者中以CD3 CD56 NKT细胞和CD3-CD56 NK细胞明显增加为主。结论CD3 CD56 NKT细胞在肺癌和乳腺癌患者的抗肿瘤效应中占据重要地位,而CD3 CD8 CTL和CD3-CD56 NK细胞在不同类型肿瘤患者中具有不同的重要性。

Research on clinical significance of CD3+CD56+NKT cells and CD3- CD56+NK cells in patients with malignant tumors

Background and objective Cytotoxic lymphocytes play an important role in anti-tumor immune. CD3 CD56 NKT cells, which are a new type of cytotoxic cells, are mainly focused on anti-tumor effect in hematologic malignancy, however its cytotoxic effects on solid tumor are not clear. The aim of this study is to explore the clinical expression and significance of peripheral CD3 CD56 NKT cells and CD3-CD56 NK cells in patients with solid malignant tumors. Methods Peripheral T cell subsets and CD3 CD56 NKT cells and CD3-CD56 NK cells in 118 patients with malignant tumors (55 lung cancers and 63 breast cancers) and 46 healthy volunteers were analysed by flow cytometer. Results Compared with healthy control, both peripheral CD3 T lymphocytes and CD3 CD4 T lymphocytes in patients with lung cancer or breast cancer significantly decreased, but CD3 CD8 T lymphocytes only increased significantly in patients with lung cancer (P<0.01). Further analysis of CD3 CD56 NKT cells and CD3-CD56 NK cells indicated that there was difference between lung cancer group and breast cancer group. In patients with lung cancer CD3 CD8 T cells and CD3 CD56 NKT cells increased significantly, and in patients with breast cancer CD3 CD56 NKT cells and CD3-CD56 NK cells increased obviously. Conclusion In patients with lung cancer or breast cancer, CD3 CD56 NKT cells play the important role in anti-tumor effects, however, the anti-tumor effects of CD3 CD8 CTL and CD3-CD56 NK cells were different.